CRDF Cardiff Oncology: רווח למניה ב-12 החודשים האחרונים

The financial price visualization for Cardiff Oncology, Inc. (CRDF) demonstrates EPS dynamics, where the current figure is 32.70. Cardiff Oncology, Inc. (CRDF) develops innovative inhibitors to combat tumor resistance while avoiding price wars. The business relies on the success of kinase drugs and their synergy with chemotherapy to extend patient survival. High-paid oncology experts lead these developments, utilizing access to cutting-edge laboratory facilities to achieve scientific breakthroughs.
CRDF (Cardiff Oncology Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The automation of cancer inhibitor design via AI and robotics at Cardiff Oncology, Inc. (CRDF) directly impacts the annual percentage change in earnings per share (TTM). This indicator captures the net income trend over the last 12 months relative to the same period last year. The calculation is based on a comparison of rolling annual EPS totals, which eliminates quarterly volatility. Growth in this metric confirms the efficiency of R&D digitalization, while a decline signals a risk of compression in investment multiples.